Patent risk alert Recent patent infringement disputes involving Truvic suggest heightened interest in secure, defensible IP and potential needs for patent analytics, litigation readiness support, and compliance tools to mitigate future IP risks.

Acquisition history Truvic was acquired by Imperative Care in 2021 and has two FDA-cleared thrombectomy systems. This indicates ongoing integration opportunities with Imperative Care’s sales channels and a potential for cross-sell of complementary devices or services.

Regulatory footprint As a medical devices company with FDA-cleared products and a small headcount, Truvic may benefit from partnerships or services that streamline regulatory submissions, post-market surveillance, and quality management across its product lifecycle.

Tech stack leverage Utilizing cloud and enterprise tools (AWS, Salesforce, Microsoft 365, DocuSign) suggests readiness for scalable deployments, CRM-driven sales motions, and potential upsell to health-tech customers seeking robust digital workflows and secure document management.

Growth potential With revenue under $1M and limited employee size, there is an opportunity to position cost-effective value propositions such as analytics, regulatory compliance, and partner-enabled sales to accelerate market reach in peripheral thrombus treatment.